Hormonal contraception update

Mayo Clinic Proceedings

Volumn 81, Issue 7, 2006, Pages 949-955

  David, Paru S ^a   Boatwright, Elizabeth A ^a   Tozer, Beverly S ^a   Verma, Deepa P ^a   Blair, Janis E ^a   Mayer, Anita P ^a   Files, Julia A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; DESOGESTREL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MESTRANOL PLUS NORETHISTERONE; MESTRANOL PLUS NORETYNODREL; NEW DRUG; NORELGESTROMIN; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT;

BREAKTHROUGH BLEEDING; DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HORMONAL CONTRACEPTION; HUMAN; IMPLANTATION; PATIENT COMPLIANCE; REVIEW; TRANSDERMAL PATCH; UNPLANNED PREGNANCY;

EID: 33745632631     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.7.949     Document Type: Article

References (35)

1. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect. 1998;30:24-29, 46.
2. Piccinino LJ, Mosher WD. Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect. 1998;30:4-10, 46.
3. Burkman R. The evolution of oral contraceptives: 40 years of continuous improvement. Clinician. 2002;20:3-30.
4. Brunton LL, Lazo JS, Parker K, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 2006.
5. Hampton RM, Short M, Bieber E, et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception. 2001;63:289-295.
6. Kaunitz AM. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial. Contraception. 2000;61;295-302.
7. Marshall J. Progestins in oral contraceptives: a comparative review. Female Patient. 2003;28:32-38.
8. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ. 2000;32:1190-1195.
9. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci. 1995;761:311-335.
10. Mishell DR Jr. Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations. Contraception. 2005;71:304-305.
11. Cedars MI. Triphasic oral contraceptives: review and comparison of various regimens. Fertil Steril. 2002;77:1-14.
12. McCoy NL, Matyas JR. Oral contraceptives and sexuality in university women. Arch Sex Behav. 1996;25:73-90.
13. Louden NB, Foxwell M, Potts DM, Guild AL, Short RV. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tricycle pill regimen. BMJ. 1977;2:487-490.
14. den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception. 1999;59:357-362.
15. Association of Reproductive Health Professionals. Extended and Continuous Use of Contraceptives to Reduce Menstruation. ARHP Clinical Proceedings; September 2004. Available at: www.arhp.org/healthcareproviders /cme/onlinecme/ReduceMensesCP/TOC.cfm. Accessed August 29, 2005.
16. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawl symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261-266.
17. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142-1149.
18. US Food and Drug Administration. FDA Approves Seasonale Oral Contraceptive; September 5, 2003. Available at: www.fda.gov/bbs/topics /ANSWERS/2003/ANS01251.html. Accessed July 8, 2005.
19. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive [published correction appears in Contraception. 2004; 69:175. Contraception. 2003;68:89-96.
20. Pfizer. Physician information: depo-subQ provera 104™ medroxyprogesterone acetate injectable suspension. Available at: www.pfizer.com/pfizer /download/uspi_depo_subq_provera.pdf. Accessed January 18, 2006.
21. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study [published correction appears in Epidemiology. 2002;13:749]. Epidemiology. 2002;13:581-587.
22. Bonny AE, Harkness LS, Cromer BA. Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female. Adolesc Med Clin. 2005;16:569-584.
23. Rivera R, Best K. Current opinion: consensus statement on intrauterine contraception. Contraception. 2002;65:385-388.
24. Mirena [package insert]. Montville, NJ: Berlex Laboratories; 2000.
25. Hidalgo M, Bahamendes L, Perrotti M, Diaz J, Danatas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002;65:129-132.
26. Association of Reproductive Health Professionals. New Developments in Intrauterine Contraception. ARHP Clinical Proceedings; September 2004. Available at: http://www.arhp.org/healthcareproviders/cme/onlinecme/IUDCP /TOC.cfm. Accessed August 29, 2005.
27. Audet MC, Moreau M, Koltun WD, et al, ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA. 2001;285:2347-2354.
28. US Food and Drug Administration. FDA Updates Labeling for Ortho Evra Contraceptive Patch. Available at: www.fda.gov/bbs/topics/news/2005 /NEW01262.html. Accessed January 18, 2006.
29. Sibai BM, Odlind V, Meador ML, Shangold GA, Fisher AC, Creasy GW. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril. 2002;77 Suppl 2:S19-S26.
30. Creasy G, Fisher A, Hall N, Shangold G. Effect of a contraceptive patch vs. placebo (PBO) on serum lipid profile [abstract]. Fertil Steril. 2000;74(suppl 1):S185.
31. Zacur HA, Hedon B, Mansour D, Shangold GA, Fisher AC, Creasy GW. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril. 2002;77(suppl 2):S32-S35.
32. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001;16:469-475.
33. Association of Reproductive Health Professionals. Periodic Well-Woman Visit: Individualized Contraceptive Care. ARHP Clinical Proceedings; May 2004. Available at: www.arhp.org/healthcareproviders/cme /onlinecme/wellwoman/TOC.cfm? ID=336. Accessed July 7, 2005.
34. Reape KZ. Curren: contraceptive research and development. Adolesc Med/Clin. 2005;16:617-633.
35. Implanon. NV Organon; c2004. Available at: www.implanon.com. Accessed September 26, 2005.